Skip to Main Content


Skip Nav Destination


Journal Archive

Cancer Immunology Research (2013-Present)

(ISSN 2326-6066) Published monthly since 2013.

Cancer Immunity (2001-2013; volumes 1-13)

(EISSN 1424-9634) Published periodically from 2001-2013.

Table of Contents

What We're Reading

In the Spotlight

Rising Stars in Cancer Immunology

Priority Brief

Targeting multiple inhibitory checkpoints of NK-cell effector function, CIS and TGFβ, unveils new combinatorial NK cell–based immunotherapy that might have broad therapeutic interventions, particularly in settings of NK cell–adoptive cell therapy.

Research Articles

The authors show CD19-expressing B-ALL cells can employ regulatory programs of normal B-cell activation and germinal center reaction to transcriptionally downregulate and maintain lower CD19 expression, allowing for enhanced survival in the early phases of CAR T-cell exposure.

Inducible Turbo (iTurbo) CAR T cells engineered to express homodimeric chimeric cytokine receptors are demonstrated to exhibit potent antitumor efficacy. Data highlight the flexibility and user-programmable nature of the iTurbo CAR T-cell platform to improve tumor control.

A radiolabeled CD69-directed antibody, [89Zr]-DFO-H1.2F3, combined with PET imaging, shows promise as a noninvasive method to assess early response to immune checkpoint blockade in vivo, with increased uptake in the tumors and lymphoid tissue of blockade-responsive tumor-bearing mice.

Long noncoding (lnc) RNA MIR4435-2HG can regulate neutrophils/PMN-MDSCs in colorectal cancer (CRC). Data identify this lncRNA as a tumor suppressor in the tumor stroma, rather than as an oncogene in tumor cells, highlighting a potential therapeutic target in CRC.

Egfr-mutant lung cancer exhibits a noninflamed tumor microenvironment (TME). Here, data demonstrate that the scheduling of EGFR inhibition with dual PD-1/VEGFR2 blockade is vital for optimum efficacy and induction of CD8+ T cell–dominant responses in the TME.

The factors that increase tumor-cell chemotactic potential to allow T-cell infiltration remain unclear. The authors find that ADAR1 induction as a result of T-cell/melanoma interactions facilitates tumor infiltration by T cells and may alter response to immunotherapy.

Sensory neurons are shown to play a critical role in the modulation of antitumor immune responses and the formation of tertiary lymphoid structures in melanoma. Data highlight afferent innervation as a potential novel target for cancer immunotherapy.

Close Modal

or Create an Account

Close Modal
Close Modal